18.53 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||18.05 x 1200|
|Ask||18.53 x 3100|
|Day's Range||18.03 - 18.55|
|52 Week Range||6.31 - 22.39|
|Beta (3Y Monthly)||2.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.36|
Silence is more “of the lambs” than golden at Aim-quoted Silence Therapeutics. Shares in the biotechnology company, which is backed by an array of high-profile institutional investors including Woodford and Invesco, have fallen from close to 250p to 58p in 18 months. Last August, Annalisa Jenkins quit after being chairwoman for 10 months.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). Arrowhead intends to initiate the adaptive design, Phase 2/3 study of ARO-AAT in patients with AATD associated liver disease at various sites in the U.S. in the second quarter of 2019, followed by various international sites in Europe, pending regulatory submission and review.
Arrowhead Pharmaceuticals, Inc. today announced the presentation of clinical data from an ongoing Phase 1/2 study of JNJ-3989 , a third-generation subcutaneously administered RNA interference therapeutic candidate being developed as a potential treatment for patients with chronic hepatitis B virus infection, at The International Liver Congress™ 2019 , the annual meeting of the European Association ...
Arrowhead Pharmaceuticals Inc. today presented preclinical data at The International Liver Congress™ 2019 , the annual meeting of the European Association for the Study of the Liver , demonstrating that sustained reduction of mutant Z-AAT protein by RNA interference substantially reversed the alpha-1 antitrypsin deficiency disease phenotype in the PiZ mouse model.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that as an inducement to entering into employment with the Company, on March 22, 2018, the Compensation Committee of the Board of Directors approved "inducement" grants to 7 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 106,000 shares of common stock. The restricted stock unit entitles one employee to receive 2,000 shares of common stock.
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
In this week's Family First segment on Yahoo Finance, we break down new concerns over kale, tax refunds, and the latest break-through for post-partum depression
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “Our discussions with the FDA have been productive and helpful as we moved through the process of determining the Phase 2/3 adaptive trial design with appropriate surrogate endpoints.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment of hypertriglyceridemia. Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “Patients with severe hypertriglyceridemia, and particularly patients with Familial Chylomicronemia Syndrome, or FCS, do not have adequate treatment options. Due to its activity as a triglyceride regulator, apoC-III has the potential to be an important therapeutic target for cardiovascular disease.
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'llRead More...
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to present at the following upcoming events:
By Brian Marckx, CFA NASDAQ:ARWR READ THE FULL RESEARCH REPORT HERE 2019 Goals Include: Data from HBV, ANG3 and APOC3 (and possibly AMG-890), Begin AAT Ph2 Program Arrowhead’s (NASDAQ:ARWR) clinical programs ...
Below are several biotech companies in the news you should know HENDERSON, NV / ACCESSWIRE / February 12, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences ...
On a per-share basis, the Pasadena, California-based company said it had net income of 13 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on February 7, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal 2019 first quarter ended December 31, 2018. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3194897. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3194897.
Among publicly tradable securities, perhaps none are more enticing than small-capitalization firms, or colloquially, small-cap stocks. Though specific definitions vary, these investments typically describe companies with market values between $300 million and $2 billion. Why would anyone want to risk their money on these speculative offers? The most obvious answer is profitability potential. Larger companies usually enjoy greater resources, and analysts as a collective force have vetted every detail. Not many surprises exist, which means these blue chips provide relatively stable trading dynamics. On the other hand, smaller firms, especially hot small-cap stocks, have an information "blackout." Analyst coverage is limited, if one is even on tap. Moreover, upstart organizations suffer a credibility gap. Almost always, they promise much upfront, but their ability to deliver over the long run remains questionable. InvestorPlace - Stock Market News, Stock Advice & Trading Tips However, this lack of information also represents the greatest strength for small-cap stocks. Like anything in life -- betting on a racehorse or drafting a franchise quarterback -- higher risks can yield higher rewards. In addition, if you're not about to retire, a controlled exposure to hot small-cap stocks is prudent. Unlike their well-capitalized counterparts, smaller firms provide explosive profitability potential over a short time frame. What it would take a Dow Jones blue chip to accomplish in 10 years can be realized within a matter of months, or even weeks. * 7 Dark Horse Stocks You Really Need to Look at for 2019 That said, you want to know when to pull the trigger, and when to call it quits. Here are five small-cap stocks that are on fire, but you shouldn't buy until the time is right: ### Crocs (CROX) Source: Shutterstock Due to its sub-$2 billion market value, Crocs (NASDAQ:CROX) fits within the accepted range of small-cap stocks. Despite my personal styling reservations, Crocs' signature shoes -- the clog-like ones manufactured with holes in them -- have fit well with customers. As a result, CROX stock has absolutely dominated Wall Street. Last year, shares doubled in value. More impressively, Crocs continued to deliver the goods throughout 2018, and carried positive momentum into the current year. So far this month, CROX has gained 8.6%. At the same time, every good thing must come to an end. CROX stock has gone too far too fast. Earlier in January, the shoemaker received a price-target upgrade from $25 to $31. Right now, we're very close to meeting this forecast. I can dive into further details, but in this case, common sense provides the best argument. Without question, CROX is one of the most intriguing hot small-cap stocks. But right now, it's overheated. ### Fossil Group (FOSL) Source: Joe King via Flickr (Modified) Famous for its stylish but accessible wristwatches, Fossil Group (NASDAQ:FOSL) has previously generated envious returns. That's not surprising considering its $800-plus million market cap. But last year, the watchmaker suffered a schizophrenic episode. In the first half of 2018, FOSL stock skyrocketed nearly 244%. But poor revenue guidance sparked a rapid deterioration in sentiment, with the second half witnessing a 41% drop. Yet Fossil Group appears to have once again won over investors. Since Christmas Eve, shares have jumped nearly 27%. Should speculators trust FOSL stock? While shares have once again entered the realm of hot small-cap stocks, a major headwind is competition. We know that Fossil has significant smartwatch cred as evidenced by Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) recent deal with them. However, smartwatches aren't unique and it's a crowded sector. * 7 Retail Stocks to Buy for the Rise of Menswear With the troubles Apple (NASDAQ:AAPL) has endured selling its once-unassailable products, it's a good idea to let Fossil cool off. ### Boyd Gaming (BYD) Source: Ace Via on Flickr With a market cap of $3 billion, gaming and hospitality outfit Boyd Gaming (NYSE:BYD) is one of the more well-resourced small-cap stocks. Given its exposure to the "vice" industry, BYD stock has natural appeal for speculators. When the economy is chugging along, consumer confidence increases, potentially resulting in higher gambling revenues. But if economic conditions deteriorate, the euphemistically-labeled "hospitality" industry offers escapism. Therefore in theory, BYD stock should witness sustained growth. Unfortunately, the second half of 2018 proved otherwise. After questions about economic stability surfaced, Boyd tumbled badly, shedding nearly 39%. However, Santa put BYD in his "nice" list. Since Christmas Eve, shares have blown up in a good way, delivering 39% returns for embattled shareholders. So is this evidence of a turnaround? I'm hesitant. Recent events like the unprecedented government shutdown have demonstrated that we're not walking on sound territory. As such, I'd wait before diving into a company so levered to consumer sentiment. ### H&E Equipment Services (HEES) Source: Daniel X O'Neil via Flickr Among hot small-cap stocks, H&E Equipment Services (NASDAQ:HEES) enjoyed a memorable run following President Donald Trump's electoral victory. A day after the historic but contentious election, HEES stock jumped nearly 18%. It's easy to see why speculators loved H&E Equipment Services. The former real-estate mogul promised big plans for his administration, chief among them the border wall. Additionally, the President has espoused a roll-up-your sleeves, "git r done" attitude. Such powerful support from the top naturally boosted HEES stock. But last November, the Democrats secured a critical victory in the midterm elections, winning a House majority. As we're witnessing with the ongoing government shutdown and associated negotiations (ie. finger pointing), Trump is unused to direct resistance. That puts H&E Equipment in a tough position. * 7 Stocks to Buy as the Dollar Weakens Moreover, we're not seeing any political headway. As it stands, we have a stubborn president and an unreasonable opposition party. So despite its massive leap forward in January, you should wait for the likely cool-off phase. ### Arrowhead Pharmaceuticals (ARWR) Source: Shutterstock Similar to other small-cap stocks, Arrowhead Pharmaceuticals (NASDAQ:ARWR) had a split personality in 2018. During the first half, ARWR stock shot into low-earth orbit, profiting speculators nearly 269%. But in the second half, Arrowhead didn't really move the needle, eventually losing more than 9%. However, recent market data suggests that ARWR stock is back to its winning form. So far this month, shares are up over 19%. Is now the time to jump aboard one of the most intriguing hot small-cap stocks? On one hand, I really love the company's biotech cred. Arrowhead specializes in RNA interference, or RNAi. This describes the natural mechanism in which living cells suppress a specific gene's activities. ARWR leverages this mechanism to help combat certain debilitating diseases. But on the flip side, meeting clinical requirements is always a tough business. Moreover, insiders have been dumping their shares since 2015. I think the wiser approach is to hold off and wait. As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Growth Stocks for the Return of the Bull * The 10 Best Index Funds to Buy and Hold * 10 Lithium Stocks to Buy Despite the Market's Irrationality Compare Brokers The post 5 Hot Small-Cap Stocks That Are a Bit Too Toasty appeared first on InvestorPlace.